Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

The histone deacetylase SIRT6 as a novel tumor suppressor that controls pancreatic cancer metabolism

FY 2012-13

Summary
Pancreatic cancer is the fourth leading cause of cancer death in Canada and one of the most aggressive and deadly malignancies. Late diagnosis and limited therapeutic options make pancreatic cancer a pressing clinical problem. In the 1920s Otto Warburg observed that cancer cells take up and use large amounts of sugar in order to support uncontrolled tumor growth. Despite being described close to a century ago, very little is known about how this change in metabolism occurs. A better understanding of this process especially in pancreatic cancer will help us to design new drugs that target the tumor cell addiction to glucose without harming normal cells. Sirtuin 6 (SIRT6) is a protein that modulates compaction of DNA (chromatin), and it has been found to be a critical regulator of genes that control glucose uptake and utilization in cells. Importantly, SIRT6 is deleted in many human pancreatic cancer cell lines and tumors. This application for a fellowship award proposes to investigate whether genetic loss of SIRT6 contributes to the development of pancreatic cancer formation. By studying gene expression and DNA compaction in pancreatic cancer cells, proposed studies will determine how SIRT6 increases glucose uptake and use. Then we will test whether restoring SIRT6 or blocking the glucose addiction will inhibit pancreatic tumor growth. Modulation of SIRT6 activity may lead to new therapies to tackle aberrant metabolism and provide new treatment options for patients with this devastating disease.
Program
CIHR Fellowship
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
269454
Name
Kugel Sita
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The histone deacetylase SIRT6 as a novel tumor suppressor that controls pancreatic cancer metabolism
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Aerobic Glycolysis; Chromatin Dynamics; Epigenetics; Pancreatic Cancer; Sirtuins; Tumor Metabolism; Tumor Suppressor
Abstract
Pancreatic cancer is the fourth leading cause of cancer death in Canada and one of the most aggressive and deadly malignancies. Late diagnosis and limited therapeutic options make pancreatic cancer a pressing clinical problem. In the 1920s Otto Warburg observed that cancer cells take up and use large amounts of sugar in order to support uncontrolled tumor growth. Despite being described close to a century ago, very little is known about how this change in metabolism occurs. A better understanding of this process especially in pancreatic cancer will help us to design new drugs that target the tumor cell addiction to glucose without harming normal cells. Sirtuin 6 (SIRT6) is a protein that modulates compaction of DNA (chromatin), and it has been found to be a critical regulator of genes that control glucose uptake and utilization in cells. Importantly, SIRT6 is deleted in many human pancreatic cancer cell lines and tumors. This application for a fellowship award proposes to investigate whether genetic loss of SIRT6 contributes to the development of pancreatic cancer formation. By studying gene expression and DNA compaction in pancreatic cancer cells, proposed studies will determine how SIRT6 increases glucose uptake and use. Then we will test whether restoring SIRT6 or blocking the glucose addiction will inhibit pancreatic tumor growth. Modulation of SIRT6 activity may lead to new therapies to tackle aberrant metabolism and provide new treatment options for patients with this devastating disease.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kugel, Sita
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
Direct Payment - $150,000 Grant (2012-13) | Canada Spends